Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer

Esteva, David; Muros, M.A.; Elvira, J.M. Llamas; Alonso, Juan Francisco Jiménez; Villar, Jesús; Torre, Martín López de la; Muros, Teresa

doi:10.1245/s10434-009-0483-8

Cited by 30 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the presence of low Tg levels, FDG-PET had an NPV of 93% [48]. Similarly, Esteva et al [49] reported FDG-PET findings in 50 patients with an elevated Tg level and a negative WBS and found that FDG-PET was positive in 32 of 39 (82.1%) patients with confirmed recurrence and negative in seven of 11 (63.6%) patients with no confirmed recurrence. The sensitivity and specificity were 82% and 64%, respectively.…”

Section: Role Of Fdg-pet In Patients With Dtc Recurrencementioning

confidence: 85%

“…Tumor size and capsular tumor invasion were factors significantly associated with a positive FDG-PET study. They also concluded that FDG-PET is an extremely useful imaging tool in patients with a negative WBS and raised Tg level [49]. The SUV max reported in patients with recurrent Hürthle cell carcinoma was remarkable.…”

Section: Role Of Fdg-pet In Patients With Dtc Recurrencementioning

confidence: 93%

See 1 more Smart Citation

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Thyroid Neoplasms

Lang

Law

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

Section: Role Of Fdg-pet In Patients With Dtc Recurrencementioning

confidence: 85%

Section: Role Of Fdg-pet In Patients With Dtc Recurrencementioning

confidence: 93%

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Thyroid Neoplasms

Lang

Law

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

“…According to the present results, vascular invasion and metastatic and lymphatic spread are all correlated with positive results on 18F-FDG PET/CT. Capsule invasion [24] or vascular invasion [25] are negative prognostic factors in DTC and positively correlate with positive 18F-FDG-PET results. Other authors [26] concluded that PET positivity correlates with extrathyroidal spread and elevated Tg in recurrent/metastatic DTC.…”

Section: Discussionmentioning

confidence: 96%

The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

Little is known about the role in ongoing risk stratification of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) performed early after radioactive iodine (RAI) ablation in differentiated thyroid carcinoma (DTC). The aim of the study is to investigate whether 18F-FDG PET/CT performed early after RAI ablation is useful to detect disease and to influence therapy and ongoing risk stratification. Patients with high/intermediate risk of recurrent DTC were included. 18F-FDG PET/CT scan was performed within 6 months after RAI ablation. We confirmed results with other imaging techniques, pathology reports, or follow-up. We classified the patient response as excellent, acceptable, or incomplete. Modified Hicks criteria were used to evaluate clinical impact. We included 81 patients with high/intermediate risk of recurrent DTC. Forty-one (50.6%) had positive uptake in 18F-FDG PET/CT, with negative (131)I whole-body scan ((131)I WBS). Sensitivity, specificity, and diagnostic accuracy of 18F-FDG PET/CT were 92.5, 90.2, and 91.4%, respectively. 18F-FDG PET/CT results had an impact on therapy in 38.3% of patients. One year after initial therapy, 45.7% showed excellent response, 8.6% acceptable response, and 45.7% incomplete response. A statistically significant relationship was found between negative 18F-FDG PET/CT and excellent response (80 vs. 12.2%, p < 0.001; OR 52.8). 18F-FDG PET/CT scan performed early in surveillance of patients with high/intermediate-risk thyroid carcinoma provides important additional information not available with conventional follow-up methods and had a high impact on therapy. A negative 18F-FDG PET/CT predicts an excellent response to therapy in the new ongoing risk stratification.

show abstract

“…In children, the neck and chest are the most likely sites of persistent disease, and contrast-enhanced imaging of these areas with CT or MRI is favored when US cannot identify disease. 18 FDG-PET/CT has become a commonly used tool in the evaluation of adults with persistent non-iodine-avid thyroid cancer (3,(321)(322)(323)(324)(325)(326) and appears to offer prognostic information that might change clinical management (327)(328)(329)(330). However, there are extremely limited data regarding the use of 18 FDG-PET/CT in children except for a case report (331), isolated pediatric subjects embedded within adult studies, and unpublished data that suggest low sensitivity of 18 FDG-PET/CT to identify residual disease in children that otherwise cannot be identified via cervical US and crosssectional imaging of the neck and chest (personal communication, SGW).…”

Section: Recommendation Rating: C and Recommendation 25(b)mentioning

confidence: 99%

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Francis

Waguespack

Bauer

et al. 2015

Thyroid

1,011

1,365

View full text Add to dashboard Cite

Background: Previous guidelines for the management of thyroid nodules and cancers were geared toward adults. Compared with thyroid neoplasms in adults, however, those in the pediatric population exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. Furthermore, therapy that may be recommended for an adult may not be appropriate for a child who is at low risk for death but at higher risk for long-term harm from overly aggressive treatment. For these reasons, unique guidelines for children and adolescents with thyroid tumors are needed. Methods: A task force commissioned by the American Thyroid Association (ATA) developed a series of clinically relevant questions pertaining to the management of children with thyroid nodules and differentiated thyroid cancer (DTC). Using an extensive literature search, primarily focused on studies that included subjects £ 18 years of age, the task force identified and reviewed relevant articles through April 2014. Recommendations were made based upon scientific evidence and expert opinion and were graded using a modified schema from the United States Preventive Services Task Force. Results: These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with DTC are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided.

show abstract

Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer

Abstract: (18)F-FDG-PET study offers a high sensitivity and positive predictive value (PPV) in patients with negative WBS and Tg positive. The use of FDG-PET is strongly recommended in DTC patients with large tumors, thyroid capsule invasion or poor-prognosis variants.

Cited by 30 publications

References 33 publications

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Thyroid Neoplasms

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Thyroid Neoplasms

The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Contact Info

Product

Resources

About